We revealed that Krm2 may promote gastric cancer proliferation and metastasis by activating PI3K/Akt pathway, and Krm2 may be a biomarker of grading and a potential therapeutic target in gastric cancer. This evidence concerns the gene AKT1 and gastric cancer.